Propel Bio Management, LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Propel Bio Management, LLC reported 21 stock positions worth $172.4 million. Its top holding was Applied Therapeutics (APLT) at 32.4% of the portfolio, followed by Plains GP (PAGP, 13.7%) and Phathom Pharmaceuticals (PHAT, 9.1%). Compared with Q2 2024, it opened 3 new positions, sold out of 6, added to 3 and reduced 3. The biggest buy was Akero Therapeutics (AKRO, shares +5%) and the biggest sale Plains GP (PAGP, shares −7%).
- Most Recent 13F
- Q2 2026
- Location
- Los Angeles, CA
- CIK
- 0001969764
- Portfolio Value
- $172.4M (Q3 2024)
- SEC Filing
- 0001829126-24-007453 ↗ filed Nov 13, 2024
Holdings Value
Holdings 21 stocks · $172.4M
| APLT Applied Therapeutics Inc. | 32.38% | 6,567,858 | $55.8M | No change |
| PAGP Plains GP Holdings LP | 13.65% | 1,272,360 | $23.5M | Reduce -7.3% |
| PHAT Phathom Pharmaceuticals Inc. | 9.12% | 869,927 | $15.7M | No change |
| ACHV Achieve Life Sciences Inc. | 6.74% | 2,453,092 | $11.6M | No change |
| TCRX Tscan Therapeutics Inc. | 6.03% | 2,087,139 | $10.4M | No change |
| AKRO Akero Therapeutics Inc. | 5.72% | 343,729 | $9.9M | Add +4.9% |
| MDGL Madrigal Pharmaceuticals Inc. | 5.30% | 43,032 | $9.1M | No change |
| RNAM Avidity Biosciences Inc. | 4.76% | 178,500 | $8.2M | No change |
| ARDX Ardelyx Inc. | 4.28% | 1,070,947 | $7.4M | Add +15.8% |
| TSAT Telesat Corp. | 2.79% | 365,781 | $4.8M | No change |
| ABEO Abeona Therapeutics Inc. | 2.29% | 624,022 | $3.9M | Reduce -50.0% |
| KYMR Kymera Therapeutics Inc. | 1.55% | 56,359 | $2.7M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 1.49% | 133,259 | $2.6M | Add +60.0% |
| KURA Kura Oncology Inc. | 1.47% | 130,000 | $2.5M | No change |
| ZVRA Zevra Therapeutics Inc. | 0.72% | 179,874 | $1.2M | New |
| EIGRQ Eiger Biopharmaceuticals Inc. | 0.72% | 146,381 | $1.2M | No change |
| ATHIRA PHARMA INC | 0.39% | 1,492,792 | $666K | No change |
| CMPS Compass Pathways PLC | 0.29% | 80,000 | $504K | New |
| VRCA Verrica Pharmaceuticals Inc. | 0.29% | 344,937 | $500K | Reduce -18.8% |
| MATPF Maat Pharma Saca | 0.01% | 2,397 | $18K | New |
| CHINOOK THERAPEUTICS CVR | 0.01% | 79,357 | $10K | No change |
Portfolio Sells Q2 2024 → Q3 2024
| PAGP Plains GP Holdings LP | Reduce -7.3% | 13.65% | −3.10 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −3.02 |
| VRCA Verrica Pharmaceuticals Inc. | Reduce -18.8% | 0.29% | −1.72 |
| ABEO Abeona Therapeutics Inc. | Reduce -50.0% | 2.29% | −1.14 |
| KYN Kayne Anderson Energy Infra | Sold out | 0.00% | −0.98 |
| TRVI Trevi Therapeutics Inc. | Sold out | 0.00% | −0.50 |
| FIDELITY INV MMTRSY 1 680 | Sold out | 0.00% | −0.21 |
| CYBIN INC | Sold out | 0.00% | −0.15 |
| MAAT PHARMA SACA | Sold out | 0.00% | −0.01 |
Portfolio Buys Q2 2024 → Q3 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 29 | $191.1M | PAGP, ACHV, CORT, PHAT, DCTH |
| Q1 2026 | 38 | $158.7M | PAGP, ACHV, PHAT, DCTH, CORT |
| Q4 2025 | 20 | $117.1M | PAGP, ACHV, PHAT, VRDN, MIST |
| Q3 2025 | 16 | $99.9M | PAGP, ACHV, AKRO, MIST, APLT |
| Q2 2025 | 16 | $82.4M | PAGP, ACHV, AKRO, PHAT, ABEO |
| Q1 2025 | 18 | $86.1M | PAGP, MDGL, AKRO, PHAT, ACHV |
| Q4 2024 | 21 | $100.7M | PAGP, MDGL, AKRO, ACHV, APLT |
| Q3 2024 | 21 | $172.4M | APLT, PAGP, PHAT, ACHV, TCRX |
| Q2 2024 | 24 | $154.2M | APLT, PAGP, TCRX, MDGL, ACHV |
| Q1 2024 | 28 | $171.8M | APLT, HIGH, TCRX, MDGL, ACHV |